Ziwei Huang, PHD, is Professor at the Burnham Institute for Medical Research and Adjunct Professor at the University of California at San Diego. He was previously Assistant Professor at Thomas Jefferson University in Philadelphia (1995-2000) and tenured Associate Professor at the University of Illinois at Urbana-Champaign (2000-2004). The author or coauthor of numerous publications and patents, Professor Huang has conducted research in cross-disciplinary areas related to drug discovery, medicinal chemistry, biochemistry, and chemical biology and has developed novel therapeutic agents and research probes for treating or studying human diseases. He has organized many international conferences and workshops in drug discovery research in America and Asia. Additionally, Professor Huang has had close interaction with the biotechnology and pharmaceutical industries as the founder of several biopharmaceutical companies and consultant for many major biotechnology and pharmaceutical companies.

"A valuable resource for scientists … Chapters in each section are filled with in-depth biological and chemical data and, importantly, include worked examples of drugs identified from these approaches." (The Biochemist, October 2008) "..the book achieves the objective of the Editor in providing a useful tool and reference for scientists concerned with state-of-the-art postgenomic drug discovery…this book will be of interest to medicinal chemistry, as well as to other concerned with developing new drug products." (Journal of Medicinal Chemistry, January 2008)

• FOREWORD. INTRODUCTION.CONTRIBUTORS.PART I. COMPUTATIONAL AND STRUCTURAL APPROACHES IN DRUG DISCOVERY.CHAPTER 1. MOLECULAR DOCKING AND STRUCTURE-BASED DESIGN (P. Therese Lang, University of California, San Francisco, CA; Tiba Aynechi, University of California, San Francisco, CA; Demetri Moustakas, University of California, Berkeley, CA; Brian Shoichet, Irwin D. Kuntz,* University of California, San Francisco, CA; Natasja Brooijmans, University of California, San Francisco, CA; and Connie M. Oshiro, Roche, Palo Alto, CA).CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS (Sutapa Ghosh (Burnham Institute for Medical Research La Jolla, CA), Aihua Nie (Burnham Institute for Medical Research La Jolla, CA), Jing An (Burnham Institute for Medical Research La Jolla, CA), and Ziwei Huang* (University of California, San Diego; Burnham Institute for Medical Research La Jolla, CA).CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY (Malcolm J. McGregor, Zhaowen Luo, and Xuliang Jiang* (Serono Research Institute, Rockland, MA).CHAPTER 4. COMPUTER-AIDED DRUG DESIGN (Grace Shiahuy Chen, Providence University, Shalu, Taiwan, Republic of China and Ji-Wang Chern,* National Taiwan University, Taipei, Taiwan, Republic of China).CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY (Weiliang Zhu (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Jian Li (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Zhen Gong (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Hong Liu (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), and Hualiang Jiang* (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China, East China University of Science and Technology, Shanghai, P.R. China).PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY.CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1 (Paul A. Wender*, Jeremy L. Baryza, Michael K. Hilinski, Joshua C. Horan, Cindy Kan, and Vishal A. Verma (Stanford University, Stanford, CA).CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) (Amanda C. Nottbohm and Paul J. Hergenrother* (University of Illinois at Urbana-Champaign, Urbana, IL).CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY (Lihe Zhang* (Peking University, Beijing, P.R. China) and Andreas H. Guse (University Hospital Hamburg—Eppendorf, Institute of Biochemistry and Molecular Biology, Hamburg, Germany).CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS (Junhai Xiao, Aihua Nie, and Song Li* (Beijing Institute of Pharmacology and Toxicology, Beijing, P.R. China).CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS (Jiange Zhang (Zhengzhou University, Zhengzhou, P.R. China) and Guoqiang Lin* (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, P.R. China).CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281Hang Yin, Gui-In Lee, and Andrew D. Hamilton*Yale University, New Haven, CTCHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS (Won-Tak Choi, University of Illinois at Urbana-Champaign, Urbana, IL; Yohichi Kumaki, Raylight Corporation, Chemokine Pharmaceutical Inc., La Jolla, CA; I. M. Krishna Kumar, Burnham Institute for Medical Research, La Jolla, CA; Jing An, Burnham Institute for Medical Research, La Jolla, CA; Douglas D. Richman, Department of Molecular Pathology, University of California, San Diego, CA; Joseph G. Sodroski, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Ziwei Huang,* University of Illinois at Urbana-Champaign, Urbana, IL, Burnham Institute for Medical Research, La Jolla, CA; Department of Molecular Pathology, University of California, San Diego, CA).CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION (Jia Hu, Yanting Guo, and Yanmei Li,* Tsinghua University, Beijing, P.R. China).CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL–GEL MATERIALS WITH TUNABLE PORE PARAMETERS (Houping Yin, Laura Zheng, and Yen Wei,* Drexel University, Philadelphia, PA).PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY.CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY (Jian-Hua Tong, Sai-Juan Chen, and Zhu Chen,* Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China).CHAPTER 16. 2-CHLORODEOXYADENOSINE (CLADRIBINE): RATIONAL DEVELOPMENT OFA NOVEL CHEMOTHERAPEUTIC AGENT (Howard B. Cottam and Dennis A. Carson,* Moores Cancer Center, University of California, San Diego, CA).CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER (John C. Reed*, Dayong Zhai, Marc Hyer, and Kate Welsh, Burnham Institute for Medical Research, La Jolla, CA).CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER’S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY, UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE (Huei-Sheng Vincent Chen*, and Stuart A. Lipton,* Burnham Institute for Medical Research, La Jolla, CA; University of California, San Diego, CA).CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES (Chi-Wai Wong and Ling Chen,* Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, P.R. China).CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES (Prithi Rajan, Kook In Park, Vaclav Ourednik, Jean Pyo Lee, Jamie Imitola, Franz-Joseph Mueller, Yang D. Teng, and Evan Snyder,* Burnham Institute for Medical Research, La Jolla, CA).INDEX.

Ziwei Huang, PHD, is Professor at the Burnham Institute for Medical Research and Adjunct Professor at the University of California at San Diego. He was previously Assistant Professor at Thomas Jefferson University in Philadelphia (1995-2000) and tenured Associate Professor at the University of Illinois at Urbana-Champaign (2000-2004). The author or coauthor of numerous publications and patents, Professor Huang has conducted research in cross-disciplinary areas related to drug discovery, medicinal chemistry, biochemistry, and chemical biology and has developed novel therapeutic agents and research probes for treating or studying human diseases. He has organized many international conferences and workshops in drug discovery research in America and Asia. Additionally, Professor Huang has had close interaction with the biotechnology and pharmaceutical industries as the founder of several biopharmaceutical companies and consultant for many major biotechnology and pharmaceutical companies.

"A valuable resource for scientists … Chapters in each section are filled with in-depth biological and chemical data and, importantly, include worked examples of drugs identified from these approaches." (The Biochemist, October 2008) "..the book achieves the objective of the Editor in providing a useful tool and reference for scientists concerned with state-of-the-art postgenomic drug discovery…this book will be of interest to medicinal chemistry, as well as to other concerned with developing new drug products." (Journal of Medicinal Chemistry, January 2008)

• FOREWORD. INTRODUCTION.CONTRIBUTORS.PART I. COMPUTATIONAL AND STRUCTURAL APPROACHES IN DRUG DISCOVERY.CHAPTER 1. MOLECULAR DOCKING AND STRUCTURE-BASED DESIGN (P. Therese Lang, University of California, San Francisco, CA; Tiba Aynechi, University of California, San Francisco, CA; Demetri Moustakas, University of California, Berkeley, CA; Brian Shoichet, Irwin D. Kuntz,* University of California, San Francisco, CA; Natasja Brooijmans, University of California, San Francisco, CA; and Connie M. Oshiro, Roche, Palo Alto, CA).CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS (Sutapa Ghosh (Burnham Institute for Medical Research La Jolla, CA), Aihua Nie (Burnham Institute for Medical Research La Jolla, CA), Jing An (Burnham Institute for Medical Research La Jolla, CA), and Ziwei Huang* (University of California, San Diego; Burnham Institute for Medical Research La Jolla, CA).CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY (Malcolm J. McGregor, Zhaowen Luo, and Xuliang Jiang* (Serono Research Institute, Rockland, MA).CHAPTER 4. COMPUTER-AIDED DRUG DESIGN (Grace Shiahuy Chen, Providence University, Shalu, Taiwan, Republic of China and Ji-Wang Chern,* National Taiwan University, Taipei, Taiwan, Republic of China).CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY (Weiliang Zhu (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Jian Li (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Zhen Gong (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Hong Liu (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), and Hualiang Jiang* (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China, East China University of Science and Technology, Shanghai, P.R. China).PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY.CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1 (Paul A. Wender*, Jeremy L. Baryza, Michael K. Hilinski, Joshua C. Horan, Cindy Kan, and Vishal A. Verma (Stanford University, Stanford, CA).CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) (Amanda C. Nottbohm and Paul J. Hergenrother* (University of Illinois at Urbana-Champaign, Urbana, IL).CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY (Lihe Zhang* (Peking University, Beijing, P.R. China) and Andreas H. Guse (University Hospital Hamburg—Eppendorf, Institute of Biochemistry and Molecular Biology, Hamburg, Germany).CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS (Junhai Xiao, Aihua Nie, and Song Li* (Beijing Institute of Pharmacology and Toxicology, Beijing, P.R. China).CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS (Jiange Zhang (Zhengzhou University, Zhengzhou, P.R. China) and Guoqiang Lin* (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, P.R. China).CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281Hang Yin, Gui-In Lee, and Andrew D. Hamilton*Yale University, New Haven, CTCHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS (Won-Tak Choi, University of Illinois at Urbana-Champaign, Urbana, IL; Yohichi Kumaki, Raylight Corporation, Chemokine Pharmaceutical Inc., La Jolla, CA; I. M. Krishna Kumar, Burnham Institute for Medical Research, La Jolla, CA; Jing An, Burnham Institute for Medical Research, La Jolla, CA; Douglas D. Richman, Department of Molecular Pathology, University of California, San Diego, CA; Joseph G. Sodroski, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Ziwei Huang,* University of Illinois at Urbana-Champaign, Urbana, IL, Burnham Institute for Medical Research, La Jolla, CA; Department of Molecular Pathology, University of California, San Diego, CA).CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION (Jia Hu, Yanting Guo, and Yanmei Li,* Tsinghua University, Beijing, P.R. China).CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL–GEL MATERIALS WITH TUNABLE PORE PARAMETERS (Houping Yin, Laura Zheng, and Yen Wei,* Drexel University, Philadelphia, PA).PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY.CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY (Jian-Hua Tong, Sai-Juan Chen, and Zhu Chen,* Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China).CHAPTER 16. 2-CHLORODEOXYADENOSINE (CLADRIBINE): RATIONAL DEVELOPMENT OFA NOVEL CHEMOTHERAPEUTIC AGENT (Howard B. Cottam and Dennis A. Carson,* Moores Cancer Center, University of California, San Diego, CA).CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER (John C. Reed*, Dayong Zhai, Marc Hyer, and Kate Welsh, Burnham Institute for Medical Research, La Jolla, CA).CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER’S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY, UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE (Huei-Sheng Vincent Chen*, and Stuart A. Lipton,* Burnham Institute for Medical Research, La Jolla, CA; University of California, San Diego, CA).CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES (Chi-Wai Wong and Ling Chen,* Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, P.R. China).CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES (Prithi Rajan, Kook In Park, Vaclav Ourednik, Jean Pyo Lee, Jamie Imitola, Franz-Joseph Mueller, Yang D. Teng, and Evan Snyder,* Burnham Institute for Medical Research, La Jolla, CA).INDEX.

Ziwei Huang, PHD, is Professor at the Burnham Institute for Medical Research and Adjunct Professor at the University of California at San Diego. He was previously Assistant Professor at Thomas Jefferson University in Philadelphia (1995-2000) and tenured Associate Professor at the University of Illinois at Urbana-Champaign (2000-2004). The author or coauthor of numerous publications and patents, Professor Huang has conducted research in cross-disciplinary areas related to drug discovery, medicinal chemistry, biochemistry, and chemical biology and has developed novel therapeutic agents and research probes for treating or studying human diseases. He has organized many international conferences and workshops in drug discovery research in America and Asia. Additionally, Professor Huang has had close interaction with the biotechnology and pharmaceutical industries as the founder of several biopharmaceutical companies and consultant for many major biotechnology and pharmaceutical companies.

"A valuable resource for scientists … Chapters in each section are filled with in-depth biological and chemical data and, importantly, include worked examples of drugs identified from these approaches." (The Biochemist, October 2008) "..the book achieves the objective of the Editor in providing a useful tool and reference for scientists concerned with state-of-the-art postgenomic drug discovery…this book will be of interest to medicinal chemistry, as well as to other concerned with developing new drug products." (Journal of Medicinal Chemistry, January 2008)

• FOREWORD. INTRODUCTION.CONTRIBUTORS.PART I. COMPUTATIONAL AND STRUCTURAL APPROACHES IN DRUG DISCOVERY.CHAPTER 1. MOLECULAR DOCKING AND STRUCTURE-BASED DESIGN (P. Therese Lang, University of California, San Francisco, CA; Tiba Aynechi, University of California, San Francisco, CA; Demetri Moustakas, University of California, Berkeley, CA; Brian Shoichet, Irwin D. Kuntz,* University of California, San Francisco, CA; Natasja Brooijmans, University of California, San Francisco, CA; and Connie M. Oshiro, Roche, Palo Alto, CA).CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS (Sutapa Ghosh (Burnham Institute for Medical Research La Jolla, CA), Aihua Nie (Burnham Institute for Medical Research La Jolla, CA), Jing An (Burnham Institute for Medical Research La Jolla, CA), and Ziwei Huang* (University of California, San Diego; Burnham Institute for Medical Research La Jolla, CA).CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY (Malcolm J. McGregor, Zhaowen Luo, and Xuliang Jiang* (Serono Research Institute, Rockland, MA).CHAPTER 4. COMPUTER-AIDED DRUG DESIGN (Grace Shiahuy Chen, Providence University, Shalu, Taiwan, Republic of China and Ji-Wang Chern,* National Taiwan University, Taipei, Taiwan, Republic of China).CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY (Weiliang Zhu (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Jian Li (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Zhen Gong (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), Hong Liu (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China), and Hualiang Jiang* (Shanghai Institute ofMateriaMedica, Chinese Academy of Sciences, Shanghai, P.R. China, East China University of Science and Technology, Shanghai, P.R. China).PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY.CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1 (Paul A. Wender*, Jeremy L. Baryza, Michael K. Hilinski, Joshua C. Horan, Cindy Kan, and Vishal A. Verma (Stanford University, Stanford, CA).CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) (Amanda C. Nottbohm and Paul J. Hergenrother* (University of Illinois at Urbana-Champaign, Urbana, IL).CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY (Lihe Zhang* (Peking University, Beijing, P.R. China) and Andreas H. Guse (University Hospital Hamburg—Eppendorf, Institute of Biochemistry and Molecular Biology, Hamburg, Germany).CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS (Junhai Xiao, Aihua Nie, and Song Li* (Beijing Institute of Pharmacology and Toxicology, Beijing, P.R. China).CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS (Jiange Zhang (Zhengzhou University, Zhengzhou, P.R. China) and Guoqiang Lin* (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, P.R. China).CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281Hang Yin, Gui-In Lee, and Andrew D. Hamilton*Yale University, New Haven, CTCHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS (Won-Tak Choi, University of Illinois at Urbana-Champaign, Urbana, IL; Yohichi Kumaki, Raylight Corporation, Chemokine Pharmaceutical Inc., La Jolla, CA; I. M. Krishna Kumar, Burnham Institute for Medical Research, La Jolla, CA; Jing An, Burnham Institute for Medical Research, La Jolla, CA; Douglas D. Richman, Department of Molecular Pathology, University of California, San Diego, CA; Joseph G. Sodroski, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Ziwei Huang,* University of Illinois at Urbana-Champaign, Urbana, IL, Burnham Institute for Medical Research, La Jolla, CA; Department of Molecular Pathology, University of California, San Diego, CA).CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION (Jia Hu, Yanting Guo, and Yanmei Li,* Tsinghua University, Beijing, P.R. China).CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL–GEL MATERIALS WITH TUNABLE PORE PARAMETERS (Houping Yin, Laura Zheng, and Yen Wei,* Drexel University, Philadelphia, PA).PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY.CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY (Jian-Hua Tong, Sai-Juan Chen, and Zhu Chen,* Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China).CHAPTER 16. 2-CHLORODEOXYADENOSINE (CLADRIBINE): RATIONAL DEVELOPMENT OFA NOVEL CHEMOTHERAPEUTIC AGENT (Howard B. Cottam and Dennis A. Carson,* Moores Cancer Center, University of California, San Diego, CA).CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER (John C. Reed*, Dayong Zhai, Marc Hyer, and Kate Welsh, Burnham Institute for Medical Research, La Jolla, CA).CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER’S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY, UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE (Huei-Sheng Vincent Chen*, and Stuart A. Lipton,* Burnham Institute for Medical Research, La Jolla, CA; University of California, San Diego, CA).CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES (Chi-Wai Wong and Ling Chen,* Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, P.R. China).CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES (Prithi Rajan, Kook In Park, Vaclav Ourednik, Jean Pyo Lee, Jamie Imitola, Franz-Joseph Mueller, Yang D. Teng, and Evan Snyder,* Burnham Institute for Medical Research, La Jolla, CA).INDEX.